Karyopharm Therapeutics Inc
$ 9.07
0.78%
04 Jun - close price
- Market Cap 203,966,000 USD
- Current Price $ 9.07
- High / Low $ 9.39 / 8.84
- Stock P/E N/A
- Book Value -11.78
- EPS -16.40
- Next Earning Report 2026-08-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.41 %
- ROE -8.91 %
- 52 Week High 10.99
- 52 Week Low 3.65
About
Karyopharm Therapeutics Inc., a pharmaceutical company, is dedicated to the discovery, development and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is headquartered in Newton, Massachusetts.
Analyst Target Price
$13.50
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-14 | 2026-02-12 | 2025-11-03 | 2025-08-11 | 2025-05-12 | 2025-02-19 | 2024-11-05 | 2024-08-06 | 2024-05-08 | 2024-02-29 | 2023-11-02 | 2023-08-02 |
| Reported EPS | -1.24 | -2.23 | -3.82 | -4.07 | -2.77 | -3.6 | -3.9 | -4.34 | -4.8 | -0.36 | -4.5 | -4.35 |
| Estimated EPS | -1.44 | -2 | -3.25 | -3.91 | -3.09 | -4.03 | -3.92 | -4.47 | -4.94 | -0.31 | -4.29 | -5.04 |
| Surprise | 0.2 | -0.23 | -0.57 | -0.16 | 0.32 | 0.43 | 0.02 | 0.13 | 0.14 | -0.05 | -0.21 | 0.69 |
| Surprise Percentage | 13.8889% | -11.5% | -17.5385% | -4.0921% | 10.356% | 10.67% | 0.5102% | 2.9083% | 2.834% | -16.129% | -4.8951% | 13.6905% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-11 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -1.39 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: KPTI
2026-06-03 22:39:34
Karyopharm Therapeutics Inc. announced it will host a virtual fireside chat on June 8, 2026, featuring its senior management and Dr. Robert Coleman, a key opinion leader in endometrial cancer. The webcast, organized by Cantor, will discuss the company's progress and the Phase 3 XPORT-EC-042 trial. Institutional investors are invited to attend, and a replay will be available online.
2026-06-02 14:40:09
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) presented positive results from its Phase 3 SENTRY trial for selinexor combined with ruxolitinib in myelofibrosis patients, meeting its co-primary endpoint for spleen volume reduction. Shares responded positively to the data, gaining over 9% in the past week and surging 138% over the past year. However, the trial did not achieve statistical significance for symptom improvement, and initial financial results showed a larger-than-expected loss for Q1 2026.
2026-06-02 14:38:54
Karyopharm Therapeutics Inc. announced that its Phase 3 SENTRY trial for selinexor plus ruxolitinib in myelofibrosis has been selected for a late-breaking oral presentation at the 2026 European Hematology Association (EHA) Congress. The presentation will highlight new data, including a post-hoc analysis suggesting that achieving a 35% or more spleen volume reduction (SVR35) may predict overall survival, and a promising overall survival signal from the combination therapy. These findings support the potential for disease modification and improved outcomes for patients with myelofibrosis.
2026-06-02 13:01:54
Karyopharm Therapeutics Inc. will present positive results from its Phase 3 SENTRY trial for selinexor plus ruxolitinib in myelofibrosis at the ASCO 2026 Annual Meeting, with simultaneous publication in the Journal of Clinical Oncology. The combination therapy showed a significant improvement in spleen volume reduction and a promising overall survival signal, suggesting a meaningful advance for patients with myelofibrosis. The treatment demonstrated a manageable safety profile consistent with the individual drugs, and evidence of potential disease modification.
2026-06-01 19:39:26
Karyopharm Therapeutics Inc. announced an inducement grant of 1,200 restricted stock units (RSUs) to a newly-hired employee. This grant was made on May 31, 2026, under the Company's 2022 Inducement Stock Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over three years, contingent on the employee's continued service.
2026-06-01 19:39:26
Karyopharm Therapeutics (Nasdaq: KPTI) announced it granted 1,200 restricted stock units (RSUs) to a new employee under its 2022 Inducement Stock Incentive Plan. The RSUs vest over three years, with 33 1/3% vesting annually, subject to continuous employment. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and is considered a routine equity compensation event.
